Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients

Autor: Marianne A B van der Sande, M. Hooiveld, Tessa M Schurink van 't Klooster, Christian J. P. A. Hoebe, Birgit H B van Benthem, Petra J. Woestenberg, Johannes A. Bogaards, Alejandra E Guevara Morel
Přispěvatelé: RS: CAPHRI - R4 - Health Inequities and Societal Participation, Sociale Geneeskunde, Epidemiology and Data Science, APH - Methodology
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Clinical Infectious Diseases, 73(2), 291-297. Oxford University Press
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Woestenberg, P J, Guevara Morel, A E, Bogaards, J A, Hooiveld, M, Schurink-Van 't Klooster, T M, Hoebe, C J P A, Van Der Sande, M A B & Van Benthem, B H B 2021, ' Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients ', Clinical Infectious Diseases, vol. 73, no. 2, pp. 291-297 . https://doi.org/10.1093/cid/ciaa582
Clinical Infectious Diseases, 73(2), 291-297
ISSN: 1058-4838
DOI: 10.1093/cid/ciaa582
Popis: Background There is ongoing debate about the possible protective effect of the bivalent human papillomavirus (2vHPV) vaccine, targeting oncogenic types HPV-16/18, against anogenital warts (AGWs), commonly attributed to HPV-6/11. We performed a retrospective registry-based open cohort study to assess the effect of 2vHPV vaccination on AGWs. Methods We linked general practice (ie, primary care) data from women born between 1993 and 2002, who had been eligible for HPV vaccination in the Netherlands, to the Dutch national immunization registry on an individual level. Women were followed until their first AGW diagnosis or end of follow-up. Adjusted incidence rate ratios (aIRRs) were estimated using Poisson regression with vaccination status as a time-dependent exposure. Results We linked data of 96 468 women with a total of 328 019 years observation time and 613 AGW diagnoses (incidence: 1.87/1000 person-years). At the end of follow-up, 61% were 2vHPV vaccinated (≥ 1 dose) of whom 91% were fully vaccinated. The AGW incidence was lower among those with ≥ 1 dose vs 0 doses (aIRR, 0.75 [95% confidence interval {CI}, .64–.88]). The effect of vaccination was stronger after full vaccination (aIRR, 0.72 [95% CI, .61–.86]) and for women who were offered vaccination at 12–13 years of age (aIRR, 0.69 [95% CI, .51–.93]) vs those at 13–16 years of age (aIRR, 0.77 [95% CI, .64–.93]). Conclusions This is the largest population-based study so far to examine the effect of 2vHPV vaccination on AGWs, with reliable individual information on AGW diagnoses and vaccination status. The results indicate that 2vHPV vaccination partially protects against AGWs, especially when administered in early adolescence.
In this large population-based cohort study linking primary care and immunization registry data, anogenital wart incidence was significantly reduced among human papillomavirus (HPV) type 16/18–vaccinated vs unvaccinated women, suggesting a partial protective effect of bivalent HPV vaccination against anogenital warts.
Databáze: OpenAIRE
Externí odkaz: